Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Petsinis et al. [7] 2017 RS 1/3 DMb 0/1 52 100% (1/1)
100% (3/3) 		100% (1/1)
NR 		NR 0% (0/1)
0% (0/3) 		NR
Krennmair et al. [71] 2010 RS 1/2 DM+RA 0/1 25 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		NR NR NR
Alenazi [84] 2021 CCS 3/NR DM+RA NR Mean: 44.6c 100% (3/3)
NR 		100% (3/3)
NR 		NR NR NR
14/39 Control group 7/7 Mean: 39.4 100% (14/14)
100% (39/39) 		100% (14/14)
NR 		Median: 0.6 NR NR
Overall
DM - RS: 2
CCS: 1 		5/5 - Ratio: 0/2 Mean: 38.5 100% (5/5)
100% (5/5) 		100% (5/5)
100% (1/1) 		NR 0% (0/1)
0% (0/3) 		NR
DM
+concomitant ADs 		- RS: 1
CCS: 1 		4/2 - Ratio: 0/1 Mean: 25 100% (4/4)
100% (2/2) 		100% (4/4)
100% (1/1) 		NR NR NR
Control group - CCS: 1 14/39 - Ratio: 1/1 Mean: 39.4 100% (14/14)
100% (39/39) 		100% (14/14)
NR 		Median: 0.6 NR NR

a = weighted mean or median; b = remission at implant placement; c = reported for RA+CTDs but NR specific for DM.
ADs = autoimmune diseases; CCS = case-control study; CTDs = connective tissue diseases; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; RA = rheumatoid arthritis; RS = retrospective study.